12 January 2021 A Phase II Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy (NECTOR Trial). View PDF
Recent News Neuroendocrine Cancer UK launches NCUK Academy Nurse Course CALLING ALL MEMBERS – CAST YOUR VOTE! UK Oncology Forum – 21st -22nd October Registration open now for KHP NET Centre 8th Annual Meeting UKI NETS 19th Annual Conference 2021 – Terms and Conditions of Virtual Event Participation
Sign up for our newsletterSign-up for our email newsletter. Simply give us your email address in the box below to sign-up.Email
